vimarsana.com

Page 3 - மருத்துவ புற்றுநோயியல் ஆண்டு சந்தித்தல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Investegate |NOVARTIS AG CHF0 50(REGD) Announcements | NOVARTIS AG CHF0 50(REGD): Novartis investigational checkpoint inhibitor tislelizumab met primary endpoint of overall survival in pivotal Phase III trial of esophageal cancer after systemic therapy

Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis investigational checkpoint inhibitor tislelizumab met primary endpoint of overall survival in pivotal Phase III trial of esophageal cancer after systemic therapy

Remote patient monitoring may reduce need to hospitalize cancer patients

Date Time Remote patient monitoring may reduce need to hospitalize cancer patients A study by researchers at Mayo Clinic Cancer Center has found that cancer patients diagnosed with COVID-19 who received care at home via remote patient monitoring were significantly less likely to require hospitalization for their illness, compared to cancer patients with COVID-19 who did not participate in the program. Results of the study were presented Friday, June 4, at the American Society of Clinical Oncology Annual Meeting and published in the Journal of Clinical Oncology. “For our study, we evaluated 224 Mayo Clinic patients with cancer who were found to have COVID-19 through standardized screening prior to receiving cancer treatment, or due to symptoms or close exposure,” says Tufia Haddad, M.D., a Mayo Clinic medical oncologist and the study’s senior author. Researchers followed the patients March 18-July 31, 2020.

Merck & Company, Inc (NYSE:MRK), Astrazeneca PLC (NYSE:AZN) - AstraZeneca, Merck Lynparza Earns Win in Early Breast Cancer, Showing Potential in Post-Surgery Setting

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.